UBS Group
KRTX

UBS Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

UBS Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-422,178
Closed -$134M – 10313
2023
Q4 		$134M Buy
422,178
+419,217
+14,158% +$81.5M 0.04% 458
2023
Q3 		$501K Sell
2,961
-13,555
-82% -$2.55M ﹤0.01% 4652
2023
Q2 		$3.58M Sell
16,516
-8,750
-35% -$1.87M ﹤0.01% 2911
2023
Q1 		$4.59M Buy
25,266
+889
+4% +$170K ﹤0.01% 2592
2022
Q4 		$4.79M Buy
24,377
+20,672
+558% +$4.43M ﹤0.01% 2541
2022
Q3 		$833K Sell
3,705
-6,234
-63% -$1.26M ﹤0.01% 3911
2022
Q2 		$1.26M Sell
9,939
-20,061
-67% -$2.31M ﹤0.01% 3532
2022
Q1 		$3.8M Buy
30,000
+28,242
+1,606% +$3.18M ﹤0.01% 2809
2021
Q4 		$230K Sell
1,758
-21,949
-93% -$2.84M ﹤0.01% 5567
2021
Q3 		$2.9M Buy
23,707
+23,096
+3,780% +$2.67M ﹤0.01% 3232
2021
Q2 		$70K Sell
611
-4,378
-88% -$512K ﹤0.01% 6146
2021
Q1 		$600K Buy
4,989
+4,285
+609% +$485K ﹤0.01% 4732
2020
Q4 		$72K Sell
704
-76
-10% -$7.04K ﹤0.01% 5915
2020
Q3 		$61K Sell
780
-1,644
-68% -$140K ﹤0.01% 5502
2020
Q2 		$271K Buy
2,424
+366
+18% +$31.8K ﹤0.01% 4589
2020
Q1 		$149K Sell
2,058
-904
-31% -$77.3K ﹤0.01% 4956
2019
Q4 		$223K Sell
2,962
-536
-15% -$23.5K ﹤0.01% 5536
2019
Q3 		$57K Buy
+3,498
New +$68K ﹤0.01% 6130

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

UBS Group's KRTX Position: Q1 2024 in Review

UBS Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 422,178 shares — an estimated $134M sold.

UBS Group first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $134M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • UBS Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 422,178 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $134M.
  • UBS Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
  • UBS Group's Karuna Therapeutics, Inc. Common Stock position peaked at $134M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.